PharmOptima LLC recognized as a Collaborator for the Spinal Muscular Atrophy Foundation

Monday, June 11, 2012

PORTAGE, MICHIGAN, June 11, 2012 – PharmOptima LLC announced that it has been recognized as a collaborator by the Spinal Muscular Atrophy Foundation, New York City.

 

Spinal Muscular Atrophy (SMA) is a motor neuron disease and the leading genetic cause of death among infants and toddlers. Characterized by selective loss of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. Patients afflicted by SMA lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe, depending on the severity of the disease. It is estimated that approximately 1 in 6,000 -10,000 infants are born with SMA.

 

Mr. Douglas Decker, Vice President at PharmOptima, said “… we are honored to be able to serve the Foundation in its ongoing quest to find a cure for this very painful and crippling disease. We will continue to help the Foundation and its other collaborators in finding a cure and we long for the day when we no longer see spinal muscular atrophy as a childhood crippler.”

Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment for Spinal Muscular Atrophy through targeted funding of clinical research and novel drug development efforts. Since its inception, the Foundation has awarded over $100 million for SMA research. In addition, the Foundation is committed to raising awareness and generating support for increased research efforts in SMA among the leaders of industry and government. For more information, visit the SMA Foundation website at www.smafoundation.org.